Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Share-based Compensation (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Share-based Compensation for 15 consecutive years, with $60492.0 as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation fell 49.23% to $60492.0 in Q4 2025 year-over-year; TTM through Oct 2025 was $257789.0, a 74.64% decrease, with the full-year FY2025 number at $478637.0, down 29.06% from a year prior.
  • Share-based Compensation was $60492.0 for Q4 2025 at PharmaCyte Biotech, roughly flat from $60492.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $913640.0 in Q3 2023 to a low of -$913640.0 in Q4 2023.
  • A 5-year average of $73353.1 and a median of $11055.0 in 2021 define the central range for Share-based Compensation.
  • Biggest YoY gain for Share-based Compensation was 33123.27% in 2023; the steepest drop was 23424.99% in 2023.
  • PharmaCyte Biotech's Share-based Compensation stood at $11055.0 in 2021, then plummeted by 64.57% to $3917.0 in 2022, then plummeted by 23424.99% to -$913640.0 in 2023, then soared by 113.04% to $119155.0 in 2024, then plummeted by 49.23% to $60492.0 in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Share-based Compensation are $60492.0 (Q4 2025), $60492.0 (Q3 2025), and $63944.0 (Q2 2025).